Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
VERU Veru Inc
5.900-0.010-0.17%
Close
01/27 16:00 ET
6.000+0.100+1.69%
Post Mkt Price 01/27 19:37 ET
High
6.090
Open
5.880
Turnover
11.05M
Low
5.810
Pre Close
5.910
Volume
1.86M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
VERU 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Veru Inc. (VERU) Investors With Significant Losses to Contact Firm's Attorneys Before Feb. 6th Deadline in Securities Class Action
San Francisco, California--(Newsfile Corp. - January 27, 2023) - Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now.Class Period: May 11, 2022 - N
VERU 12-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Veru Inc. (VERU) Investors With Significant Losses to Contact Firm's Attorneys Before Feb. 6th Deadline in Securities Class Action
San Francisco, California--(Newsfile Corp. - January 25, 2023) - Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now.Class Period: May 11, 2022 - N
VERU Investors Have Opportunity to Lead Veru Inc. Securities Fraud Lawsuit
LOS ANGELES, Jan.
Veru Call Volume Above Normal and Directionally Bullish
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Veru Inc. (VERU) Investors to Approaching Deadline in Securities Class Action, Encourages Investors With Significant Losses to Contact Firm's Attorneys
San Francisco, California--(Newsfile Corp. - January 20, 2023) - Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now. Class Period: May 11, 2022 -
HAGENS BERMAN Encourages Veru Inc. (VERU) Investors With Significant Losses to Contact Firm's Attorneys Before Feb. 6th Deadline in Securities Class Action
San Francisco, California--(Newsfile Corp. - January 18, 2023) - Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now. Class Period: May 11, 2022 -
VERU ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Veru Inc. Shareholders
NEW YORK, Jan. 17, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Veru Inc. (NASDAQ: VERU) alleging that the Company viol
Those Who Invested in Veru (NASDAQ:VERU) Five Years Ago Are up 364%
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Veru Inc. (VERU) Investors With Significant Losses to Contact Firm's Attorneys Before Feb. 6th Deadline in Securities Class Action
San Francisco, California--(Newsfile Corp. - January 13, 2023) - Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now.Class Period: May 11, 2022 - N
A Great Week That Adds to Veru Inc.'s (NASDAQ:VERU) One-year Returns, Institutional Investors Who Own 49% Must Be Happy
If you want to know who really controls Veru Inc. (NASDAQ:VERU), then you'll have to look at the makeup of its share registry. With 49% stake, institutions possess the maximum shares in the company.
Company Overview
More
Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm’s breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. The company’s sexual health business’ commercial product is the FC2 Female Condom/FC2 Internal Condom, an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections which is sold commercially and in the public health sector both in the U.S. and globally. Veru was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1996 and is headquartered in Miami, FL.
CEO： Dr. Mitchell S. Steiner
Market： NASDAQ
Listing Date： 07/01/1990
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet